21 November 2018
Vol 10, Issue 468

About The Cover

Cover image expansion

ONLINE COVER Hampering Hantavirus. There are no targeted treatments for hantavirus cardiopulmonary syndrome, which can be caused by different types of hantaviruses that circulate in rodents. To develop therapeutics for this potentially fatal disease, Garrido et al. isolated memory B cells from people who had survived infection with Andes hantavirus (pictured here). Antibodies isolated from these B cells were tested for hantavirus neutralization in vitro. Two potently neutralizing antibodies protected hamsters from fatal infection, even when the antibodies were given three days after the virus. These antibodies could potentially be administered to patients infected with hantavirus as post-exposure therapy. [CREDIT: JAMES CAVALLINI/SCIENCE SOURCE]